The noncoding genome, defined as the DNA content of an organism that does not encode for proteins, holds most of the regulatory elements of the genome. These DNA elements control the identity and the biology of any cell, and in humans, the amount of noncoding DNA is almost a hundred times higher than protein-coding sequences. The expression of a given protein-coding gene can therefore be controlled by multiple noncoding elements, including the gene's promoter, enhancers, or neighboring genes encoding long noncoding RNAs (lncRNAs). In this issue of Cell, Cho et al. (2018) identify the promoter of the PVT1 gene as a DNA element that regulates the expression of its neighbor, the oncogene MYC, in a manner independent of PVT1 lncRNA. The study shows that the PVT1 promoter limits MYC transcription by competing in cis for the use of specific enhancers, acting as a DNA boundary element (Figure 1) .
Such multi-component control of gene expression clearly allows a finer regulation of gene expression. However, it also implies that the malfunctioning of the noncoding element could positively or negatively affect a target gene and eventually cause disease. Previous studies have shown that the genomic region containing MYC and PVT1 is frequently amplified in cancer and that the lncRNA PVT1 acts as an oncogene by stabilizing MYC protein (Cui et al., 2016; Tseng et al., 2014) . However, some cancer genomes also show structural variations of the PVT1 locus that impair lncRNA transcription, suggesting that additional DNA elements at the locus could regulate cell proliferation and tumorigenesis. To address this issue, Cho et al. (2018) analyze the results of a previous study that used CRISPR interference (CRISPRi) on cell proliferation. In that study, different single-guide RNAs locate the catalytically dead Cas9 (dCas9) protein fused with a repressive effector domain (KRAB) to specific sites in the locus (Liu et al., 2017) . The dCas9-KRAB is shown to enhance breast-cancer-cell proliferation only when positioned at the most upstream PVT1 promoter, which is opposite of the oncogenic function of PVT1 lncRNA, suggesting that its promoter alone has a tumor suppression function. Transcriptome analysis identified MYC as the major effector of the proliferative outcome induced by CRISPRi of PVT1, strengthening the evidences on the functional correlation between these two genes.
Although intriguing and unexpected, the induction of MYC transcription by silencing of the PVT1 promoter does not exclude the possibility that the lncRNA itself has an independent role. A scenario whereby the function of the lncRNA is linked to both the RNA product and other attributes of the gene locus has in fact been described for other lncRNA loci (reviewed in Marchese et al. [2017] ). To understand this issue, Cho et al. (2018) lower PVT1 RNA level using different approaches, such as via dCas9-mediated transcriptional block and siRNA-or antisense-oligonucleotide-mediated depletion. In all these cases, the reduction of the lncRNA has no effect on MYC levels, supporting the notion that MYC expression and cell growth are regulated by the promoter of PVT1 and not by its lncRNA product.
MYC is the closest neighbor gene of PVT1 but is 53 kb away, and this relatively long distance confounds an easy explanation for how the PVT1 promoter acts on MYC transcription. Chromosomes are organized in topologically associated domains (TADs), 3D structures that form at genomic regions whose DNA sequences preferentially contact each other (Acemel et al., 2017) . Moreover, MYC is known to contact a number of long-range regulatory elements (Sotelo et al., 2010) . Is the stretch between PVT1 promoter and MYC part of a shared 3D chromatin conformation? Are the two genes in the same TAD? To answer these questions, the authors use the HiChIP method to directly capture long-range interactions in the genome mediated by the enhancerassociated mark histone H3K27 acetylation. In this way, the PVT1 promoter is shown to frequently interact with both the MYC promoter and a series of four intragenic enhancers within the PVT1 gene, all of them belonging to the same TAD. Most interestingly, in CRISPRi-PVT1 cells, PVT1 promoter repression increases the number of interactions between MYC and the intragenic enhancers, suggesting that the PVT1 promoter serves as a competitor to limit the transcription of MYC. This conclusion is supported by additional evidence that also reveals the mechanism of action. For instance, CRISPR activation of PVT1 decreases MYC transcription. Moreover, the allelic analysis of the murine orthologs Pvt1 and myc in neuronal precursor cells shows an inverse correlation between their expression and promoter accessibility when located in the same allele, supporting the idea that the regulation occurs in cis and in an allele-specific manner. However, given that the effect of PVT1 promoter on MYC is dependent on the topological conformation of the locus, it seems to depend on the cell's identity, and is not observed in all cell types, such as mouse embryonic cells or the human colorectal cancer cell line HCT116. This role as a ''counter-enhancer'' for a DNA element with an already ascribed function reveals yet again how much is left to understand regarding enhancer function in gene regulation. While previous work has pointed toward mechanisms that involve enhancer competition (reviewed in Long et al. [2016] ), future studies are needed to understand if promoter competition is a more general mechanism adopted during evolution to regulate gene expression.
Given the relevance of MYC in cancer biology (Dang, 2012) and the results obtained by Cho et al. (2018) , it is to be expected that somatic mutations in the PVT1 promoter should appear more frequently in cancer cells. Indeed, by analyzing cancer genomes from a variety of tumor types, Cho et al. (2018) find a significant enrichment in somatic structural variants, such as deletions, inversions, and duplications at the PVT1 promoter both compared to other regions of the locus and to other lncRNA promoters. These observations are experimentally corroborated by CRISPR-mediated mutations of the PVT1 promoter that confer a growth advantage to the genome-edited cells compared to cells containing the wild-type sequence. The PVT1 promoter can therefore be seen as a new type of tumor suppressor candidate. It will be interesting to investigate if this ''non-canonical'' tumor suppressor could be exploited to design a new therapeutic strategy in those tumors where MYC is the cancer driver.
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Figure 1. PVT1 Regulates MYC Expression by Promoter Competition
(A) The PVT1 promoter contacts the MYC promoter and a number of PVT1 intragenic enhancers (822E, 866E, 912E, and 919E) within the same topologically associated domain (TAD). The enhancers interact preferentially with the PVT1 promoter and support the expression of the lncRNA-PVT1. (B) When the PVT1 promoter is not functional-for instance, in cancer cells that harbor mutations in the promoter region or in cells where the promoter has been experimentally repressed (CRISPRi-PVT1)-the four enhancers are no longer able to interact with the PVT1 promoter and make contact with the MYC locus. This increases MYC expression and promotes cancer cell proliferation.
